Evoke Pharma, Inc. announced that the United States Patent and Trademark Office (USPTO) issued US patent No. 11,628,150 under the title "Nasal Formulations of Metoclopramide." This patent expires in 2029 and covers the nasal solution of metoclopramide and its characteristics when formulated. The patent augments Evoke's existing patent portfolio, which includes U.S. Food and Drug Administration (FDA) Orange Book-listed patents and other patents in the EU, Japan, Canada, and Mexico.

The Company will seek to list this patent in the FDA Orange-Book in the near term.